Epidemiology of COVID-19 in Tehran, Iran: A Cohort Study of Clinical Profile, Risk Factors, and Outcomes.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
10
2021
revised:
27
01
2022
accepted:
06
04
2022
entrez:
20
5
2022
pubmed:
21
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
The outbreak of coronavirus disease 2019 (COVID-19) dates back to December 2019 in China. Iran has been among the most prone countries to the virus. The aim of this study was to report demographics, clinical data, and their association with death and CFR. This observational cohort study was performed from 20th March 2020 to 18th March 2021 in three tertiary educational hospitals in Tehran, Iran. All patients were admitted based on the WHO, CDC, and Iran's National Guidelines. Their information was recorded in their medical files. Multivariable analysis was performed to assess demographics, clinical profile, outcomes of disease, and finding the predictors of death due to COVID-19. Of all 5318 participants, the median age was 60.0 years, and 57.2% of patients were male. The most significant comorbidities were hypertension and diabetes mellitus. Cough, dyspnea, and fever were the most dominant symptoms. Results showed that ICU admission, elderly age, decreased consciousness, low BMI, HTN, IHD, CVA, dialysis, intubation, Alzheimer disease, blood injection, injection of platelets or FFP, and high number of comorbidities were associated with a higher risk of death related to COVID-19. The trend of CFR was increasing (WPC: 1.86) during weeks 25 to 51. Accurate detection of predictors of poor outcomes helps healthcare providers in stratifying patients, based on their risk factors and healthcare requirements to improve their survival chance.
Sections du résumé
Background
UNASSIGNED
The outbreak of coronavirus disease 2019 (COVID-19) dates back to December 2019 in China. Iran has been among the most prone countries to the virus. The aim of this study was to report demographics, clinical data, and their association with death and CFR.
Methods
UNASSIGNED
This observational cohort study was performed from 20th March 2020 to 18th March 2021 in three tertiary educational hospitals in Tehran, Iran. All patients were admitted based on the WHO, CDC, and Iran's National Guidelines. Their information was recorded in their medical files. Multivariable analysis was performed to assess demographics, clinical profile, outcomes of disease, and finding the predictors of death due to COVID-19.
Results
UNASSIGNED
Of all 5318 participants, the median age was 60.0 years, and 57.2% of patients were male. The most significant comorbidities were hypertension and diabetes mellitus. Cough, dyspnea, and fever were the most dominant symptoms. Results showed that ICU admission, elderly age, decreased consciousness, low BMI, HTN, IHD, CVA, dialysis, intubation, Alzheimer disease, blood injection, injection of platelets or FFP, and high number of comorbidities were associated with a higher risk of death related to COVID-19. The trend of CFR was increasing (WPC: 1.86) during weeks 25 to 51.
Conclusions
UNASSIGNED
Accurate detection of predictors of poor outcomes helps healthcare providers in stratifying patients, based on their risk factors and healthcare requirements to improve their survival chance.
Identifiants
pubmed: 35592525
doi: 10.1155/2022/2350063
pmc: PMC9113873
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2350063Informations de copyright
Copyright © 2022 Hamidreza Hatamabadi et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
PLoS One. 2020 Jul 9;15(7):e0235458
pubmed: 32645044
PLoS One. 2020 Jul 30;15(7):e0236618
pubmed: 32730358
JAMA Netw Open. 2020 Dec 1;3(12):e2029058
pubmed: 33301018
PLoS One. 2020 Jun 25;15(6):e0235107
pubmed: 32584868
Eur Respir J. 2020 Aug 6;56(2):
pubmed: 32444412
JAMA. 2017 Jul 25;318(4):360-370
pubmed: 28742910
PLoS One. 2020 Dec 14;15(12):e0243966
pubmed: 33318711
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1873-1874
pubmed: 32998094
Lancet Respir Med. 2020 Sep;8(9):853-862
pubmed: 32735842
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Crit Care Med. 2021 Feb 1;49(2):209-214
pubmed: 33105150
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
J Hosp Med. 2021 Feb;16(2):90-92
pubmed: 33147129
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
BMJ. 2020 Sep 4;370:m3379
pubmed: 32887691
J Res Med Sci. 2021 Nov 29;26:114
pubmed: 35126577
Lancet Public Health. 2020 Jun;5(6):e311
pubmed: 32334648
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
JAMA Netw Open. 2020 Dec 1;3(12):e2026881
pubmed: 33275153
J Med Virol. 2022 Jan;94(1):110-118
pubmed: 34387886
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
PLoS One. 2020 Jun 23;15(6):e0234765
pubmed: 32574165
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
Nutrition. 2021 Nov-Dec;91-92:111408
pubmed: 34388589
Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3400-3403
pubmed: 32271458
Expert Rev Anti Infect Ther. 2022 Apr;20(4):631-641
pubmed: 34753363
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
J Intern Med. 2020 Oct;288(4):469-476
pubmed: 32498135
Biometrics. 2012 Jun;68(2):598-606
pubmed: 22276951
Respir Med. 2021 May;181:106384
pubmed: 33839587
J Diabetes Res. 2020 Nov 17;2020:5436832
pubmed: 33294461
Dis Markers. 2022 Jan 20;2022:5106342
pubmed: 35096202
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Adv Exp Med Biol. 2021;1321:199-210
pubmed: 33656725
Curr Biol. 2017 Jul 24;27(14):R713-R715
pubmed: 28743020
Eur J Pharmacol. 2021 Mar 5;894:173854
pubmed: 33428898
Front Med (Lausanne). 2021 Jul 21;8:626321
pubmed: 34368174
Sci Total Environ. 2021 Feb 10;755(Pt 1):142523
pubmed: 33022464
Adv Exp Med Biol. 2021;1321:245-251
pubmed: 33656729
Int J Stroke. 2020 Jun;15(4):385-389
pubmed: 32310015
BMJ. 2020 May 22;369:m1985
pubmed: 32444460